Cargando…
P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403043/ http://dx.doi.org/10.1016/S2152-2650(22)00491-8 |
| _version_ | 1784773282320351232 |
|---|---|
| author | Spiliopoulou, Vassiliki Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Gavriatopoulou, Maria Theodorakakou, Foteini Fotiou, Despina Migkou, Magdalini Roussou, Maria Eleutherakis-Papaiakovou, Evangelos Kastritis, Efstathios Dimopoulos, Meletios A. Terpos, Evangelos |
| author_facet | Spiliopoulou, Vassiliki Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Gavriatopoulou, Maria Theodorakakou, Foteini Fotiou, Despina Migkou, Magdalini Roussou, Maria Eleutherakis-Papaiakovou, Evangelos Kastritis, Efstathios Dimopoulos, Meletios A. Terpos, Evangelos |
| author_sort | Spiliopoulou, Vassiliki |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9403043 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94030432022-08-25 P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study Spiliopoulou, Vassiliki Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Gavriatopoulou, Maria Theodorakakou, Foteini Fotiou, Despina Migkou, Magdalini Roussou, Maria Eleutherakis-Papaiakovou, Evangelos Kastritis, Efstathios Dimopoulos, Meletios A. Terpos, Evangelos Clin Lymphoma Myeloma Leuk Poster Presentations Elsevier Inc. 2022-08 2022-08-25 /pmc/articles/PMC9403043/ http://dx.doi.org/10.1016/S2152-2650(22)00491-8 Text en Copyright © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Poster Presentations Spiliopoulou, Vassiliki Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Gavriatopoulou, Maria Theodorakakou, Foteini Fotiou, Despina Migkou, Magdalini Roussou, Maria Eleutherakis-Papaiakovou, Evangelos Kastritis, Efstathios Dimopoulos, Meletios A. Terpos, Evangelos P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study |
| title | P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study |
| title_full | P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study |
| title_fullStr | P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study |
| title_full_unstemmed | P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study |
| title_short | P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study |
| title_sort | p-161: oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and covid-19; a singlecenter, prospective study |
| topic | Poster Presentations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403043/ http://dx.doi.org/10.1016/S2152-2650(22)00491-8 |
| work_keys_str_mv | AT spiliopoulouvassiliki p161oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT ntanasisstathopoulosioannis p161oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT malandrakispanagiotis p161oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT gavriatopouloumaria p161oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT theodorakakoufoteini p161oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT fotioudespina p161oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT migkoumagdalini p161oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT roussoumaria p161oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT eleutherakispapaiakovouevangelos p161oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT kastritisefstathios p161oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT dimopoulosmeletiosa p161oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT terposevangelos p161oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy |